Rabies virus glycoprotein g, polynucleotide, and infectious disease vaccine containing same
By designing a mutated rabies virus glycoprotein G and optimizing the polynucleotide sequence, combined with murine BAFF mRNA and a lipid nanoparticle delivery system, the prepared mRNA rabies vaccine solves the problems of short-lasting immune response and safety of existing vaccines, achieving a highly efficient and safe immunization effect.
Patent Information
- Application Number
- PCT/CN2026/095698
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-08
- Filing Date
- 2026-05-08
- Publication Date
- 2026-11-12
AI Technical Summary
Existing rabies virus mRNA vaccines have not been able to effectively overcome the heterogeneity of rabies virus glycoprotein G, resulting in a short-lasting immune response. Furthermore, traditional inactivated vaccines have low virus yield, high cost, and potential tumor risks.
An amino acid mutant of rabies virus glycoprotein G was designed, and the polynucleotide sequence was optimized to improve RNA stability and translation efficiency. Combined with mouse BAFF mRNA and a lipid nanoparticle delivery system, an mRNA rabies vaccine was prepared.
It achieves a higher level of neutralizing antibody induction, with better immunization effect than inactivated vaccines, higher safety, lower immune side effects, and lower immunization dose.
Smart Images

Figure PCTCN2026095698-FTAPPB-I100001 
Figure PCTCN2026095698-FTAPPB-I100002 
Figure PCTCN2026095698-FTAPPB-I100003
Abstract
Description
A rabies virus glycoprotein G, polynucleotide, and a vaccine containing it for infectious diseases. Technical Field
[0001] This invention relates to the fields of biomedicine and virology, specifically to a rabies virus glycoprotein G, polynucleotide, and a vaccine containing the same. Background Technology
[0002] Rabies is a severe zoonotic disease caused by the rabies virus (RV), with a near 100% mortality rate. Currently, there is no effective treatment; prevention is the only option. In my country, post-exposure prophylaxis is more cost-effective than pre-exposure prophylaxis and has become the primary method of prevention. The rabies virus belongs to the family Rhabdoviridae and the genus Lyssavirus. Its virus particles are bullet-shaped and consist of an outer shell and a core. The viral genome is a single-stranded, non-segmented, negative-sense RNA, approximately 12 kb in size. After exposure, there is an incubation period, followed by flu-like symptoms, eventually leading to progressive encephalomyelitis and severe neurological atrophy.
[0003] The rabies virus glycoprotein (RabvG protein) is the main immunoprotective antigen of the rabies virus and the only viral component present in all proposed new rabies vaccines. The G protein is relatively conserved and can induce the production of specific neutralizing antibodies and stimulate cellular immunity, playing a decisive role in resisting rabies virus attack. RabvG exists in multiple conformations and readily transitions between its pre-fusion and post-fusion conformations, as well as between monomeric and trimeric states. This heterogeneity of RabvG may prevent the immune system from generating a durable post-vaccination immune response to the rabies virus.
[0004] Currently, the main rabies vaccines used in my country are inactivated vaccines, such as human diploid cell (HDC) vaccines and purified Vero cell rabies vaccines (PVRV). While these vaccines are effective in preventing the spread of rabies, they still have shortcomings, such as slow HDC proliferation, low viral yield, high vaccine cost, and the potential risk of tumor formation due to residual DNA in purified Vero cells. mRNA vaccines, due to their low risk of in vivo recombination mutations, high immunogenicity, short development cycle, simple production facilities, and short vaccine production cycle, can compensate for the shortcomings of inactivated vaccines and have broad prospects. Currently, some mRNA vaccines containing the rabies virus G protein coding region are in the laboratory or clinical research stage, such as those from CureVac in Germany, GSK in the UK, and Zhuhai Lifanda in China. However, none of these have overcome the drawbacks caused by the heterogeneity of RabvG. Rabies prevention and control still requires safer and more effective rabies virus mRNA vaccines, which will provide a new technological means for rabies control. Summary of the Invention
[0005] To overcome the lack of effective rabies virus mRNA vaccines in the prior art, this invention provides a rabies virus glycoprotein G, polynucleotide, and infectious disease vaccine containing it, as well as its application.
[0006] The first aspect of the present invention provides a rabies virus glycoprotein G, the sequence of which is shown in SEQ ID NO:1; or, the sequence of the rabies virus glycoprotein G has at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with the amino acid sequence shown in SEQ ID NO:1, and retains the function of the amino acid sequence shown in SEQ ID NO:1.
[0007] A second aspect of the present invention provides a polynucleotide encoding a recombinant rabies virus glycoprotein; the ORF sequence of the polynucleotide is shown in SEQ ID NO:3-13; or, the ORF sequence of the polynucleotide has at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with the nucleotide sequence shown in SEQ ID NO:3-13, and retains the function of the nucleotide sequence shown in SEQ ID NO:3-13.
[0008] In some implementations, the polynucleotide is RNA.
[0009] In some implementations, the polynucleotide is mRNA.
[0010] In some preferred embodiments, the polynucleotide further comprises one or more of 5'-UTR, 3'-UTR, and 3'poly(A).
[0011] In some preferred embodiments, the nucleotide sequence of the 5'-UTR is as shown in SEQ ID NO:15 or SEQ ID NO:18; the nucleotide sequence of the 3'-UTR is as shown in SEQ ID NO:16 or SEQ ID NO:19; the 3'poly(A) comprises 50-120 adenosine nucleotides; the 3'poly(A) preferably comprises 100 adenosine nucleotides.
[0012] A third aspect of the present invention provides a polynucleotide composition comprising the polynucleotide as described in the first aspect of the present invention and mouse BAFF mRNA.
[0013] In some preferred embodiments, the nucleic acid sequence of the mouse-derived BAFF is shown in SEQ ID NO:20.
[0014] In some implementations, the mouse-derived BAFF mRNA and the polynucleotide described in the first aspect of the present invention are not in the same polynucleotide.
[0015] In some implementations, the murine BAFF mRNA and the polynucleotide described in the first aspect of the present invention are within the same polynucleotide.
[0016] A fourth aspect of the present invention provides a recombinant expression vector comprising a polynucleotide as described in the second aspect of the present invention or a polynucleotide composition as described in the third aspect of the present invention.
[0017] In some preferred embodiments, the backbone of the recombinant expression vector is a plasmid or a virus, such as pUC-Kan-TMA.
[0018] A fifth aspect of the present invention provides a transformant comprising a polynucleotide as described in the second aspect of the present invention, a polynucleotide composition as described in the third aspect of the present invention, or a recombinant expression vector as described in the fourth aspect of the present invention.
[0019] In some preferred embodiments, the starting cell of the transformant is a eukaryotic cell.
[0020] In some preferred embodiments, the eukaryotic cells are mammalian cells.
[0021] In some further preferred embodiments, the mammalian cells are human somatic cells.
[0022] The sixth aspect of the present invention provides a method for preparing recombinant rabies virus glycoprotein, the method comprising culturing a transformant as described in the fifth aspect of the present invention under conditions suitable for the expression of the recombinant rabies virus glycoprotein.
[0023] A seventh aspect of the present invention provides a polynucleotide delivery system comprising (1) a polynucleotide as described in the second aspect of the present invention, a polynucleotide composition as described in the third aspect of the present invention, a recombinant expression vector as described in the fourth aspect of the present invention, or a transformant as described in the fifth aspect of the present invention; and (2) a delivery vector.
[0024] In some preferred embodiments, the delivery carrier is a lipid nanoparticle.
[0025] In some preferred embodiments, the lipid nanoparticles comprise cationic lipids, non-cationic lipids, sterols, and polyethylene glycol-modified lipids.
[0026] In some preferred embodiments, the lipid nanoparticles include the adjuvant compound HA-1A.
[0027] An eighth aspect of the present invention provides a pharmaceutical composition comprising rabies virus glycoprotein G as described in the first aspect of the present invention or a polynucleotide delivery system as described in the seventh aspect of the present invention; optionally, it further comprises pharmaceutically acceptable excipients.
[0028] The ninth aspect of the present invention provides an mRNA rabies vaccine, the mRNA rabies vaccine comprising rabies virus glycoprotein G as described in the first aspect of the present invention, a polynucleotide as described in the second aspect of the present invention, a polynucleotide composition as described in the third aspect of the present invention, a polynucleotide delivery system as described in the seventh aspect of the present invention, and / or a pharmaceutical composition as described in the eighth aspect of the present invention.
[0029] In some preferred embodiments, the mRNA rabies vaccine further comprises a pharmaceutically acceptable adjuvant.
[0030] In one embodiment, the mRNA rabies vaccine is administered via subcutaneous injection, intramuscular injection, or intraperitoneal injection.
[0031] The tenth aspect of the present invention provides a reagent kit or cassette, characterized in that the reagent kit or cassette comprises rabies virus glycoprotein G as described in the first aspect of the present invention, a polynucleotide as described in the second aspect of the present invention, a polynucleotide composition as described in the third aspect of the present invention, a recombinant expression vector as described in the fourth aspect of the present invention, a transformant as described in the fifth aspect of the present invention, a polynucleotide delivery system as described in the seventh aspect of the present invention, a pharmaceutical composition as described in the eighth aspect of the present invention, and / or an mRNA rabies vaccine as described in the ninth aspect of the present invention.
[0032] The eleventh aspect of the present invention provides the use of rabies virus glycoprotein G as described in the first aspect of the present invention, polynucleotides as described in the second aspect of the present invention, polynucleotide compositions as described in the third aspect of the present invention, recombinant expression vectors as described in the fourth aspect of the present invention, transformants as described in the fifth aspect of the present invention, polynucleotide delivery systems as described in the seventh aspect of the present invention, pharmaceutical compositions as described in the eighth aspect of the present invention, mRNA rabies vaccines as described in the ninth aspect of the present invention, and / or kits or cassettes as described in the tenth aspect of the present invention in the preparation of drugs and / or diagnostic reagents for the prevention and treatment of rabies virus infection.
[0033] The twelfth aspect of the present invention provides a rabies virus glycoprotein G as described in the first aspect of the present invention, a polynucleotide as described in the second aspect of the present invention, a polynucleotide composition as described in the third aspect of the present invention, a recombinant expression vector as described in the fourth aspect of the present invention, a transformant as described in the fifth aspect of the present invention, a polynucleotide delivery system as described in the seventh aspect of the present invention, a pharmaceutical composition as described in the eighth aspect of the present invention, an mRNA rabies vaccine as described in the ninth aspect of the present invention, and / or a kit or cassette as described in the tenth aspect of the present invention for the prevention and treatment of diseases caused by rabies virus.
[0034] The thirteenth aspect of the present invention provides a method for preventing and treating rabies virus infection, the method comprising administering to a subject an effective dose of rabies virus glycoprotein G as described in the first aspect of the present invention, a polynucleotide as described in the second aspect of the present invention, a polynucleotide composition as described in the third aspect of the present invention, a recombinant expression vector as described in the fourth aspect of the present invention, a transformant as described in the fifth aspect of the present invention, a polynucleotide delivery system as described in the seventh aspect of the present invention, a pharmaceutical composition as described in the eighth aspect of the present invention, an mRNA rabies vaccine as described in the ninth aspect of the present invention, and / or a kit or cassette as described in the tenth aspect of the present invention.
[0035] In some preferred embodiments, the administration is performed using a 1-1-1-1 immunization schedule, a 2-1-1-1 immunization schedule, a 2-2 immunization schedule, a 2-1 immunization schedule, or a 2-1-1 immunization schedule.
[0036] In some preferred embodiments, the administration is performed according to a 2-1-1 immunization schedule. In some further preferred embodiments, the administration is performed by intramuscular, subcutaneous, or intraperitoneal injection; the dose is 0.08–10 μg, preferably 0.08–2.5 μg, more preferably 0.08–2 μg.
[0037] In some implementations, the subject is a mammal.
[0038] In some implementations, the mammal is a human, dog, cat, ferret, rabbit, cow, horse, monkey, or hyena.
[0039] In some implementations, the mammal is a human.
[0040] Based on common knowledge in the field, the above-mentioned preferred conditions can be combined arbitrarily to obtain various preferred embodiments of the present invention.
[0041] The reagents and raw materials used in this invention are all commercially available.
[0042] The positive and progressive effects of this invention are as follows:
[0043] The rabies virus glycoprotein G, polynucleotide, composition, vaccine formulation, and method of the present invention also have at least one of the following beneficial effects:
[0044] (1) After the amino acid mutation of rabies virus glycoprotein G, it has obtained a differentiated dimer conformation compared with wild-type rabies virus glycoprotein G, which can induce a higher level of neutralizing antibody titer in vivo.
[0045] (2) After sequence codon optimization, RNA stability increases, mRNA translation efficiency improves, and immunogenicity is stronger;
[0046] (3) It exhibits more persistent cell surface expression compared to the natural sequence;
[0047] (4) Inducing high levels of binding and neutralizing antibodies against the rabies virus G protein in subjects.
[0048] (5) The immunization dose is low, and the immunization effect is better than that of commercially available inactivated vaccines, which is reflected in the high antibody level and the ability to induce stronger neutralizing antibody levels in the early stage.
[0049] (6) It has a low risk of adverse immune response and is safer than inactivated vaccines, with a smaller negative impact on the subject’s weight and weight gain. Attached Figure Description
[0050] Figure 1 shows the structural design and efficacy validation of the mutant rabies virus glycoprotein G: (A) Comparison of the wild-type and mutant structures of the RABV-G protein; (B) The titer levels of neutralizing antibodies against rabies virus glycoprotein G in mouse serum induced by mRNA vaccines (10 μg) and inactivated vaccines (1 / 10 human dose) encoding different rabies virus glycoprotein G.
[0051] Figure 2 shows the construction and in vitro validation of the rabies virus mRNA vaccine; (A) Schematic diagram of mRNA vaccine preparation; (B) Western blotting analysis of LNP-mRNA (Ori, Opti-1, Opti-2, Opti-3, Opti-4, Opti-5, Opti-6, Opti-7, Opti-8, Opti-9, Opti-10, and Opti-11) expression in A549 cells. The ratio of the grayscale of the target band to the total protein content was used as the relative expression level for comparison. The NC group served as the negative control group.
[0052] Figure 3 shows the immunogenicity of the LNP-mRNA formulation of the present invention in mice; Immunogenicity (AD) of the LNP-mRNA vaccine and the inactivated vaccine three-dose regimen: (A) Experimental protocol of vaccination with the LNP-mRNA formulation of the present invention (5 μg or 10 μg) and human rabies vaccine (1 / 10 human dose); (B) Titer levels of neutralizing antibodies against rabies virus glycoprotein G in mouse serum induced by different sequence mRNA vaccines (10 μg) and inactivated vaccines (1 / 10 human dose); (C-1) EC50 of neutralizing antibodies against rabies virus glycoprotein G in mouse serum induced by Opti-11 mRNA vaccine (10 μg) and inactivated vaccines (1 / 10 human dose); (C-2) Opti-11 mRNA vaccine (10 μg) and inactivated vaccines (1 / 10 human dose). (C-3) Titer levels of neutralizing antibodies against rabies virus glycoprotein G in mouse serum induced by different doses and injection numbers of Opti-11 mRNA vaccine; (D) Titer levels of binding antibodies against rabies virus glycoprotein G in mouse serum induced by different sequence mRNA vaccines (5 μg); Immunogenicity of LNP-mRNA vaccine and inactivated vaccine three-dose regimen (EF): (E) Experimental protocol for inoculation with the LNP-mRNA preparation (5 μg) of the present invention and human rabies vaccine (1 / 10 human dose); (F-1) Titer levels of binding antibodies against rabies virus glycoprotein G in mouse serum induced by different sequence mRNA vaccines (5 μg) and inactivated vaccine (1 / 10 human dose); (F-2) Titer levels of binding antibodies against rabies virus glycoprotein G in mouse serum induced by different sequence mRNA vaccines (5 μg) and inactivated vaccine (1 / 10 human dose); EC50 levels of antibodies binding to rabies virus glycoprotein G in mouse serum induced by dose; results are shown as geometric mean ± SEM, N = 4–5 (number).
[0053] Figure 4 shows the neutralizing antibody titer levels against rabies virus (RABV) pseudovirus in the serum of mice immunized with Opti-11 LNP-mRNA formulations (2.5 μg, 5 μg and 10 μg / dose) under different immunization schedules (D0, D0 / D7) (results are shown as geometric mean ± SEM).
[0054] Figure 5 shows the immunogenicity comparison between LNP-Opti mRNA vaccine and Benchmark mRNA vaccine. (A) BALB / c mice (n=4) were vaccinated with LNP-mRNA vaccine (5 μg / dose) on D0 / D7, and the neutralizing antibody level was tested by blood samples collected on D28 after the first immunization. (B) The neutralizing antibody titer levels against rabies virus (RABV) pseudovirus induced in the serum of mice 28 days after immunization under the immunization schedule (D0 / D7) of Opti-8 LNP formulation with self-developed UTR and control UTR and LNP formulation expressing Benchmark mRNA of the same antigen (5 μg / dose). (C) Immunogenicity comparison of Opti-1 and Opti-8 LNP formulations with control UTR (5 μg / dose) on the immunization schedule (D0 / D7) of mice 28 days after immunization, the neutralizing antibody titer levels against rabies virus (RABV) pseudovirus induced in the serum of mice. (Results are shown as geometric mean ± SEM).
[0055] Figure 6 shows the enhanced immunogenicity of LNP formulations using Opt-1 mRNA and murine BAFF mRNA. BALB / c mice (n=3–4) were vaccinated on day 0 with an LNP-mRNA vaccine containing Opt-1 mRNA (5 μg / dose) and murine BAFF mRNA (5 μg / dose), and a control LNP-Opti-1 mRNA vaccine (5 μg / dose). Neutralizing antibody levels were measured by blood samples taken on day 7 after the first immunization. (Results are shown as geometric mean ± SEM).
[0056] Figure 7 shows the enhanced immunogenicity of LNP-Opti-1 mRNA when used in combination with the adjuvant compound HA-1A. BALB / c mice (n=3–4) were vaccinated on day 0 with LNP-Opti-1 mRNA (5 μg / dose) without the adjuvant compound and LNP-Opti-1 mRNA vaccine (5 μg / dose) containing the adjuvant compound. EC50 was measured on days 5 and 7 after the first immunization. (Results are shown as geometric mean ± SEM). Detailed Implementation
[0057] General definitions and terms
[0058] All patents, patent applications, scientific publications, manufacturers' specifications and guidelines, etc., cited herein, are incorporated herein in their entirety, whether mentioned above or below. Nothing herein should be construed as an admission that this disclosure is not entitled to precede such disclosure.
[0059] Unless otherwise stated, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. Furthermore, the terms related to protein and nucleic acid chemistry, molecular biology, cell and tissue culture, and microbiology used herein are all widely used terms in their respective fields (see, for example, *Molecular Cloning: A Laboratory Manual, 2nd Edition*, J. Sambrook et al. eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor 1989). To better understand this invention, definitions and explanations of related terms are provided below.
[0060] As used herein, the expressions “comprising,” “including,” “containing,” and “having” are open-ended, meaning they include the listed elements, steps, or components but do not exclude other unlisted elements, steps, or components. The expression “consisting of” excludes any unspecified elements, steps, or components. The expression “substantially consisting of” is limited to the specified elements, steps, or components, plus optional elements, steps, or components that do not significantly affect the essential and novel nature of the claimed subject matter. It should be understood that the expressions “substantially consisting of” and “consisting of” are encompassed within the meaning of the expression “including.”
[0061] As used herein, unless the context otherwise indicates, the singular expressions “a,” “an,” or “this” include plural references. The terms “one or more” or “at least one” cover 1, 2, 3, 4, 5, 6, 7, 8, 9, or more.
[0062] The list of ranges of values in this document is provided solely as a shorthand method for individually referring to each distinct value falling within the range. Unless otherwise stated herein, each individual value is included in this specification as it is individually listed herein. Unless explicitly stated otherwise, all numerical values or ranges shown herein are modified with “about”, indicating that the listed or claimed numerical values or ranges are ±20%, ±10%, ±5%, or ±3%.
[0063] Unless otherwise stated, all methods described herein may be performed in any suitable order.
[0064] As used herein, the term "wildtype" means that the sequence is naturally occurring and has not been artificially modified, including naturally occurring mutants.
[0065] As used herein, the term "% identity" for sequences refers to the percentage of identical nucleotides or amino acids in the best alignment between sequences to be compared. Differences between two sequences can be distributed across local regions (segments) or the entire length of the sequences being compared. Identity between two sequences is typically determined after the best alignment of a segment or "comparison window." Best alignment can be performed manually or with the aid of algorithms known in the art, including but not limited to the local homology algorithms described in Smith and Waterman, 1981, Ads App. Math. 2, 482 and Neddleman and Wunsch, 1970, J. Mol. Biol. 48, 443, the similarity search methods described in Pearson and Lipman, 1988, Proc. Natl Acad. Sci. USA 88, 2444, or using computer programs such as GAP, BESTFIT, FASTA, BLAST P, BLAST N, and TFASTA from the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Drive, Madison, Wis. For example, the percentage identity of two sequences can be determined using the BLASTN or BLASTP algorithms publicly available on the National Center for Biotechnology Information (NCBI) website.
[0066] The percentage of identity is obtained by determining the number of identical positions corresponding to the sequences to be compared, dividing this number by the number of positions being compared (e.g., the number of positions in the reference sequence), and multiplying the result by 100. In some embodiments, the degree of identity is given for at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, or about 100% of the region. In some embodiments, the degree of identity is given for the entire length of the reference sequence. Sequence identity can be determined using tools known in the art, preferably using optimal sequence alignment, such as Align, using standard settings, preferably EMBOSS:needle, Matrix:Blosum62, Gap Open 10.0, or Gap Extend 0.5.
[0067] In this article, "nucleotide" includes deoxyribonucleotides and ribonucleotides and their derivatives. As used herein, "ribonucleotide" is the building block of ribonucleic acid (RNA), consisting of one base, one pentose sugar, and one phosphate molecule; it refers to a nucleotide with a hydroxyl group at the 2' position of the β-D-ribofuranosyl group. "Deoxyribonucleotide," on the other hand, is the building block of deoxyribonucleic acid (DNA), also consisting of one base, one pentose sugar, and one phosphate molecule; it refers to a nucleotide where the hydroxyl group at the 2' position of the β-D-ribofuranosyl group is replaced by hydrogen, and it is a major chemical component of chromosomes. Nucleotides are usually identified by a single letter representing the bases in them: "A(a)" refers to deoxyadenosine or adenosine containing adenine, "C(c)" refers to deoxycytidine or cytidine containing cytosine, "G(g)" refers to deoxyguanosine or guanosine containing guanine, "U(u)" refers to uridine containing uracil, and "T(t)" refers to deoxythymidine containing thymine.
[0068] As used herein, the terms "polynucleotide" and "nucleic acid" are used interchangeably to refer to polymers of deoxyribonucleotides (DNA) or polymers of ribonucleotides (RNA). "Polynucleotide sequence," "nucleic acid sequence," and "nucleotide sequence" are used interchangeably to indicate the sequence of nucleotides in a polynucleotide. Those skilled in the art will understand that the DNA coding strand (sense strand) and its encoded RNA can be considered to have the same nucleotide sequence, with the deoxythymidine nucleotide in the DNA coding strand sequence corresponding to the uridine nucleotide in its encoded RNA sequence. In this document, for RNA sequence descriptions, U(u) and T(t) are used interchangeably because the character U(u) is not permitted according to the current WIPO sequence listing format; T(t) is used to represent thymine and uracil for both RNA and DNA sequences.
[0069] As used herein, the term “expression” includes the transcription and / or translation of a nucleotide sequence. Therefore, expression can involve the production of transcripts and / or peptides. The term “transcription” refers to the process of transcribing the genetic code in a DNA sequence into RNA (transcription). The term “in vitro transcription” refers to the in vitro synthesis of RNA, particularly mRNA, in a cell-free system (e.g., in a suitable cell extract) (see, e.g., Pardi N., Muramatsu H., Weissman D., Karikó K. (2013). In: Rabinovich P. (eds) Synthetic Messenger RNA and Cell Metabolism Modulation. Methods in Molecular Biology (Methods and Protocols), vol 969. Humana Press, Totowa, NJ.). Vectors that can be used to produce transcripts are also called “transcription vectors,” which contain the regulatory sequences required for transcription. The term “transcription” encompasses “in vitro transcription.”
[0070] As used in this article, "encoding" refers to the inherent characteristics of a specific nucleotide sequence in a polynucleotide. For example, genes, cDNA, or mRNA can serve as templates to synthesize polymers and macromolecules in other biological processes, as long as a definite nucleotide sequence or a definite amino acid sequence is available. Therefore, a gene encoding a protein means that the gene's mRNA produces a protein in a cell or other biological system through transcription and translation.
[0071] The term "amino acid" also refers to naturally occurring and synthetic amino acids as amino acid analogs and amino acid mimics, which function similarly to the 30 naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those formed through modification, such as hydroxyproline, γ-carboxyglutamic acid, and O-phosphoserine. Amino acid analogs are those that have the same basic chemical structure as natural amino acids, i.e., an α-carbon bonded to hydrogen, a carboxyl group, an amino group, and an R group, such as homoserine, ortholeucine, methionine sulfoxide, and methionine methylsulfonamide. Such analogs have modified R groups (e.g., ortholeucine) or modified peptide backbones, but retain the same basic chemical structure of a naturally occurring amino acid. Amino acid mimics are those that have a structure different from the general chemical structure of amino acids, but function similarly to naturally occurring amino acids.
[0072] Amino acids can be represented by their commonly used three-letter symbols or by a naming committee consisting of single-letter symbols recommended by IUPAC-IUB Biochemicals. Similarly, nucleotides can also be represented by their commonly accepted single-letter codes.
[0073] As used herein, the term "peptide" refers to a polymer containing two or more "amino acids" covalently linked by peptide bonds. A "protein" may contain one or more polypeptides, wherein the polypeptides interact with each other covalently or non-covalently. Unless otherwise stated, "peptide" and "protein" are used interchangeably.
[0074] The following eight groups of amino acids each contain a conserved substituted amino acid: 1) alanine (A), glycine (G); 2) aspartic acid (D), glutamic acid (E), 30-asparagine (N), glutamine (Q); 4) arginine (R), lysine (K); 5) isoleucine (I), leucine (L), methionine (M), valine (V); 6) phenylalanine (F), tyrosine (Y), tryptophan (W); 7) serine (S), threonine (T); and 8) cysteine (C), methionine (M).
[0075] As used herein, the term "transformer" refers to a cell used to receive, maintain, replicate, or express a polynucleotide or vector. In some embodiments, the transformant may be a cell in which the polypeptide of the present invention is expressed.
[0076] As used herein, an "antigen" is a molecule that, upon entering the body, can elicit an adaptive immune response, which may involve antibody production, specific immunogenic cells, or both. Those skilled in the art will understand that any macromolecule, including virtually all proteins or peptides, can serve as an antigen. Furthermore, antigens can be derived from recombinant or genomic DNA or RNA. Those skilled in the art will understand that any DNA or RNA used herein, whose nucleotide sequence or a portion thereof can encode a protein capable of evoking adaptive immunity. It is evident that the present invention includes, but is not limited to, the use of partial nucleotide sequences of more than one gene, and these nucleotide sequences forming different mixtures to induce a response. Furthermore, those skilled in the art will understand that an antigen does not need to be entirely encoded by a single gene. It is evident that antigens can be synthesized or derived from biological samples. Biological samples include, but are not limited to, tissue samples, tumor samples, cells, or biological fluids.
[0077] As used in this article, an "antibody" is a protective protein produced by the body in response to antigen stimulation. It is an immunoglobulin produced by B lymphocytes. The monomer of an antibody is a Y-shaped molecule composed of four polypeptide chains. These include two identical heavy chains and two identical light chains linked together by disulfide bonds. Each heavy chain is approximately 50 kDa, and each light chain is approximately 25 kDa, with disulfide bonds linking the heavy and light chains. Its unique characteristic lies in its high affinity and specificity for its binding partners.
[0078] As used herein, "vaccine" refers to a composition comprising an active ingredient (such as the polynucleotide of the present invention) that can elicit an immune response in a recipient through inoculation. In specific embodiments, the immune response it induces provides immune protection and is sufficient to prevent and / or alleviate at least one symptom associated with a pathogen or disease infection. According to the present invention, the polynucleotide or composition described herein can be used as a vaccine to provide prophylactic and / or therapeutic immunization against rabies virus in subjects in need.
[0079] As used herein, the term "neutralizing antibody" refers to an antibody or fragment thereof that is capable of neutralizing, i.e., preventing, inhibiting, reducing, or interfering with the ability of a pathogen to initiate and / or maintain infection in a host (e.g., a host organism or host cell). According to the present invention, neutralizing antibodies against rabies virus glycoprotein G can be generated in subjects vaccinated with the vaccine of the present invention, for example, in the subject's immune serum. The level of neutralizing antibody titers in the immune serum can be measured using methods known in the art.
[0080] Rabies virus
[0081] As used in this article, the term "rabies virus" is a rhabdovirus containing single-stranded, unsegmented, negative-sense RNA, and is the pathogen of rabies. Its viral RNA encodes five major proteins: nucleoprotein (N-protein), phosphoprotein (P-protein), matrix protein (M-protein), glycoprotein (G-protein), and RNA-dependent RNA polymerase (L-protein).
[0082] The glycoprotein (G protein) is a membrane protein on the surface of the rabies virus particle, approximately 67 kDa. It forms the viral spikes in a trimer form and is the virus's most important and effective protective antigen, inducing the body to produce neutralizing antibodies and cellular immune responses. As used in this article, the term "Pitman Moore (PM) strain" refers to the rabies virus strain recommended by the WHO for the preparation of human inactivated rabies vaccines; it is the PM strain with NCBI registration number 11292. The PM strain is a vaccine strain that meets the relevant national and WHO requirements and quality standards for human vaccine production, and its G protein is shown in the NCBI sequence number CAI43218.1.
[0083] polypeptide
[0084] In general, the polynucleotide-encoded polypeptide of the present invention has at least 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity with the amino acid sequence of SEQ ID NO:1. The rabies virus glycoprotein G having the amino acid sequence of SEQ ID NO:1 is the glycoprotein G containing the H289A mutation of the rabies virus vaccine strain Pitman Moore (PM). The polynucleotide-encoded polypeptide of the present invention can be used as a polypeptide antigen to induce a protective immune response against rabies infection in subjects.
[0085] Polynucleotides
[0086] This invention provides polynucleotides encoding recombinant rabies virus glycoprotein. The polynucleotides can be single-stranded or double-stranded. Polynucleotides include, but are not limited to, DNA, cDNA, RNA (e.g., mRNA), recombinant-generated, and chemically synthesized polynucleotides. The polynucleotides can be contained in a vector. The polynucleotides of this invention can include naturally occurring, synthetic, and modified nucleotides. In some embodiments, the polynucleotides of this invention are used to express the polypeptides described herein in cells to provide a polypeptide antigen. In some embodiments, the polypeptide antigen can induce an immune response against rabies virus glycoprotein G in suitable subjects.
[0087] The polynucleotide may comprise one or more segments (nucleotide fragments) (e.g., segments 1, 2, 3, 4, 5, 6, 7, and 8). The polynucleotide may comprise a segment encoding a polypeptide of interest (e.g., the polypeptides and polypeptide antigens described herein). In a particular embodiment, the polynucleotide may comprise a coding sequence for the polypeptide of interest as well as regulatory sequences (including, but not limited to, transcriptional and translational regulatory sequences). In one embodiment, the regulatory sequence comprises one or more of the following: a promoter sequence, a 5' untranslated region (5'UTR) sequence, a 3' untranslated region (3'UTR) sequence, and a poly(A) sequence.
[0088] Encoded sequence
[0089] As used herein, a "coding sequence" refers to a polynucleotide sequence that can serve as a template for the synthesis of a defined nucleotide sequence (e.g., tRNA and mRNA) or a defined amino acid sequence in a biological process. The coding sequence can be a DNA sequence or an RNA sequence. If an mRNA corresponding to a DNA sequence (including a coding strand identical to the mRNA sequence and a template strand complementary to it) is translated into a polypeptide in a biological process, the DNA sequence or mRNA sequence can be considered to encode the polypeptide.
[0090] As used herein, a "codon" refers to a sequence of three consecutive nucleotides (also known as a triplet codon) in a polynucleotide that encodes a specific amino acid. Synonymous codons (codons encoding the same amino acid) are used with varying frequencies in different species, a phenomenon known as "codon bias." It is generally accepted that, for a given species, the coding sequence using its preferred codons will have higher translation efficiency and accuracy in that species' expression system. Therefore, polynucleotides can be "codon optimized," i.e., the codons in the polynucleotide can be changed to reflect the codons preferred by the host cell, preferably without altering the encoded amino acid sequence. Those skilled in the art will understand that, due to codon degeneracy, the polynucleotides of this invention can contain coding sequences that differ from those described herein (e.g., having approximately 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity with the coding sequences described herein) but encode the same amino acid sequence. In a particular embodiment, the RNA of the present invention contains codons optimized for host (e.g., subject, particularly human) cells, such that the polypeptide of the present invention is optimally expressed in the host (e.g., subject, particularly human).
[0091] In one embodiment, the sequence encoded by the polynucleotide of the present invention contains a start codon at its 5' end and a stop codon at its 3' end. In one embodiment, the coding sequence contains the open reading frame (ORF) as described herein.
[0092] In one embodiment, the polynucleotide described herein comprises: (1) a nucleotide sequence of one of SEQ ID NO:3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13; and (2) a nucleotide sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with a nucleotide sequence of one of SEQ ID NO:3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or 13.
[0093] In one embodiment, the coding sequence of the polypeptide described herein comprises a nucleotide sequence comprising: (1) a preferred nucleotide sequence of SEQ ID NO:3-13; and (2) a nucleotide sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with the preferred nucleotide sequence of SEQ ID NO:3-13.
[0094] RNA
[0095] In some embodiments, the polynucleotide of the present invention is RNA. As used herein, the definition of "RNA" encompasses single-stranded, double-stranded, linear, and circular RNA. The RNA of the present invention can be chemically synthesized, recombinant-produced, or transcribed in vitro. In one embodiment, the RNA of the present invention is used to express the polypeptide of the present invention in a host cell.
[0096] In one embodiment, the RNA of the present invention is a single-stranded RNA. In another embodiment, the RNA of the present invention is in vitro transcribed RNA (IVT-RNA). IVT-RNA can be obtained by in vitro transcription using an RNA polymerase with a DNA template (e.g., as described herein).
[0097] In some embodiments, the RNA of the present invention is messenger RNA (mRNA). Generally, the mRNA may comprise a 5'-UTR sequence, a coding sequence, a 3'-UTR sequence, and optionally a poly(A) sequence and a signal peptide coding sequence. The mRNA can be produced, for example, by in vitro transcription or chemical synthesis. In one embodiment, the mRNA of the present invention is obtained by in vitro transcription using a DNA template via an RNA polymerase (e.g., T7 RNA polymerase). In one embodiment, the mRNA of the present invention comprises (1) a 5'-UTR, (2) a polypeptide coding sequence, (3) a 3'-UTR, (4) an optionally present poly(A) sequence, and (5) a signal peptide coding sequence. The 5'-UTR, polypeptide coding sequence, 3'-UTR, and poly(A) sequence are as described herein. In one embodiment, the mRNA of the present invention is a nucleoside-modified mRNA. In one embodiment, the mRNA of the present invention comprises an optionally present 5' cap.
[0098] In some embodiments, the RNA of the present invention comprises a coding sequence for a recombinant rabies virus glycoprotein.
[0099] In some embodiments, the RNA of the present invention also includes structural elements that help improve RNA stability and / or translation efficiency, including but not limited to 5' cap, 5'-UTR, 3'-UTR and poly(A) sequence.
[0100] As used herein, the term "untranslated region (UTR)" generally refers to a region in RNA (such as mRNA) that is not translated into an amino acid sequence (non-coding region), or the corresponding region in DNA. Typically, a UTR located at the 5' end (upstream) of an open reading frame (start codon) can be called a 5'-UTR; a UTR located at the 3' end (downstream) of an open reading frame (stop codon) can be called a 3'-UTR. In the presence of a 5' cap, the 5'-UTR is downstream of the 5' cap, for example, directly adjacent to it. In certain embodiments, an optimized "Kozak sequence" may be included in the 5'-UTR, for example, near the start codon, to improve translation efficiency. In the presence of a poly(A) sequence, the 3'-UTR is upstream of the poly(A) sequence, for example, directly adjacent to it.
[0101] In a preferred embodiment, the 5'-UTR comprises the preferred nucleotide sequences of SEQ ID NO:15 and 18. In a preferred embodiment, the 3'-UTR comprises the preferred nucleotide sequences of SEQ ID NO:16 and 19. In some embodiments, the RNA of the present invention comprises both a 5'-UTR and a 3'-UTR.
[0102] As used herein, the term "poly(A) sequence" or "poly(A) tail" refers to a nucleotide sequence containing continuous or discontinuous adenosine nucleotides. The poly(A) sequence is typically located at the 3' end of RNA, such as the 3' end (downstream) of a 3'-UTR. In some embodiments, the poly(A) sequence does not contain nucleotides other than adenosine nucleotides at its 3' end. In other embodiments, the poly(A) sequence contains one or more nucleotides other than adenosine nucleotides at its 3' end, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides; preferably 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15; more preferably 7, Eight, nine, ten, eleven, twelve, or thirteen nucleotides; particularly preferred are ten guanosine, uridine, or cytidine, with cytidine being the most preferred; the Poly(A) sequence can be generated during IVT-RNA preparation by transcription of the coding sequence of the DNA template by a DNA-dependent RNA polymerase, or by linking it to the free 3' end of the IVT-RNA, such as the 3' end of the 3'-UTR, by a DNA-independent RNA polymerase (poly(A) polymerase).
[0103] In some embodiments, the RNA of the present invention comprises a poly(A) sequence. In one embodiment, the poly(A) sequence comprises consecutive adenosine nucleotides. In one embodiment, the poly(A) sequence may comprise at least 20, 30, 40, 50, 60, 70, 75, 80, 85, 95, or 100 adenosine nucleotides, and up to 120, 150, 180, 200, or 300 adenosine nucleotides. Preferably, the poly(A) sequence comprises 100 adenosine nucleotides. In one embodiment, the continuous adenosine sequence in the poly(A) sequence is interrupted by a sequence containing U, C, or G nucleotides, for example, by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides containing U, C, or G; preferably 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 nucleotides; more preferably 7, 8, 9, 10, 11, 12, or 13 nucleotides; and most preferably by a sequence interrupted by 10 nucleotides containing U, C, or G. In other embodiments, the sequence containing U, C, or G nucleotides that interrupts the continuous adenosine sequence in the poly(A) sequence is one or more, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, preferably 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15, more preferably 7, 8, 9, 10, 11, 12, or 13, and most preferably 10.
[0104] The poly(A) sequence may contain at least 20, 30, 40, 50, 60, 70, 75, 80, 85, 95, or 100 nucleotides, and up to 120, 150, 180, 200, or 300 nucleotides. In one embodiment, the poly(A) sequence contains at least 50 nucleotides. In one embodiment, the poly(A) sequence contains at least 80 nucleotides. In one embodiment, the poly(A) sequence contains at least 100 nucleotides. In some embodiments, the poly(A) sequence contains about 70, 80, 90, 100, 120, or 150 nucleotides. In a specific embodiment, the poly(A) sequence contains 100 nucleotides.
[0105] As used herein, the term "5' cap" generally refers to an N7-methylguanosine structure (also known as "m7G cap" or "m7Gppp-") that is linked to the 5' end of mRNA via a 5'-to-5' triphosphate bond. The 5' cap can be co-transcribed into RNA during in vitro transcription (e.g., using an anti-reverse cap analogue "ARCA"), or it can be ligated into RNA post-transcriptionally using a capping enzyme.
[0106] In one embodiment, the RNA of the present invention comprises the nucleotide sequence of any one of SEQ ID NO: 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 and 13.
[0107] In one embodiment, the RNA of the present invention (a) comprises a nucleotide sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identity with the preferred nucleotide sequences in SEQ ID NO:3-13; and (b) encodes an amino acid sequence having at least 95% identity with the amino acid sequence of SEQ ID NO:1.
[0108] Modified nucleotides
[0109] In some embodiments, the nucleotides in the RNA (e.g., mRNA) of the present invention can be naturally occurring nucleotides (e.g., naturally occurring ribonucleotides) and modified nucleotides. Modified nucleotides can be, for example, nucleotides not present in naturally occurring RNA, such as non-standard nucleotides or deoxynucleotides. Nucleotide modification can occur on the nucleoside, for example, on the ribose moiety and / or the nucleobase moiety. Modified nucleotides can be incorporated during transcription (e.g., in vitro transcription) or added during RNA chemical synthesis.
[0110] In one embodiment, the RNA is modified by comprising one or more modified nucleosides. In one embodiment, the RNA is modified by replacing one or more uridines with a modified uridine. In one embodiment, the modified uridine includes 1-methylpseudouridine, pseudouridine, 5-methyluridine, or combinations thereof.
[0111] Examples of modified uridine may include, but are not limited to: 1-methyluridine, 1-methyl-pseudouridine, 3-methyl-uridine, 3-methyl-pseudouridine, 2-methoxy-uridine, 5-methoxy-uridine, 5-aza-uridine, 6-aza-uridine, 2-thio-5-aza-uridine, 2-thio-uridine, 4-thio-uridine, 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxy-uridine, 5-aminoallyl-uridine, 5-halo-uridine, uridine 5-oxyacetic acid, uridine 5-oxyacetic acid methyl ester, 5-carboxymethyl-uridine, 1-carboxymethyl-pseudouridine, 5-carboxyhydroxymethyl-uridine, 5-carboxyhydroxymethyl 5-methoxycarbonylmethyl-uridine, 5-methoxycarbonylmethyl-2-thio-uridine, 5-aminomethyl-2-thio-uridine, 5-methylaminomethyl-uridine, 1-ethyl-pseudouridine, 5-methylaminomethyl-2-thio-uridine, 5-carbamoylmethyl-uridine, 5-carboxymethylaminomethyl-uridine, 5-carboxymethylaminomethyl-2-thio-uridine, 5-propynyl-uridine, 1-propynyl-pseudouridine, 5-tauronic acid methyl-uridine, 1-tauronic acid methyl-pseudouridine, 5-tauronic acid methyl-2-thio-uridine, 1-tauronic acid methyl-4-thio-pseudouridine, 5-methyl-2 -Thio-uridine, 1-methyl-4-thio-pseudouridine, 4-thio-1-methyl-pseudouridine, 2-thio-1-methyl-pseudouridine, 1-methyl-1-denitro-pseudouridine, 2-thio-1-methyl-1-denitro-pseudouridine, dihydrouridine (D), dihydropseudouridine, 5,6-dihydrouridine, 5-methyl-dihydrouridine, 2-thio-dihydrouridine, 2-thio-dihydrouridine, 2-thio-dihydropseudouridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine, 4-methoxy-2-thio-pseudouridine, 3-(3-amino-3-carboxypropyl)uridine, 5-(isopentenylaminomethyl)uridine, 5-(isopentenylamino)uridine 5,2'-2-thiouridine, α-thiouridine, 2'-O-methyluridine, 5,2'-O-dimethyluridine, 2'-O-methyl-pseudouridine, 2-thio-2'-O-methyluridine, 5-methoxycarbonylmethyl-2'-O-methyluridine, 5-carbamoylmethyl-2'-O-methyluridine, 5-carboxymethylaminomethyl-2'-O-methyluridine, 3,2'-O-dimethyluridine, 5-(isopentenylaminomethyl)-2'-O-methyluridine, 1-thiouridine, 5-(2-methoxycarbonylvinyl)uridine, and 5-[3-(1-E-propenylamino)]uridine.
[0112] In one embodiment, the RNA (e.g., mRNA) of the present invention is modified by comprising one or more modified nucleotides. In one embodiment, the modified nucleotides include modified cytosine, modified uracil, or combinations thereof. In one embodiment, the modified uracil is independently selected from pseudouracil, 1-methyl-pseudouracil, 5-methyl-uracil, or combinations thereof. In one embodiment, the modified cytosine is independently selected from 5-methylcytosine, 5-hydroxymethylcytosine, or combinations thereof. In one embodiment, the proportion of modified nucleotides in the RNA of the present invention is 10%-100%, meaning that the RNA of the present invention can be modified by replacing 10%-100% of its nucleotides with modified nucleotides.
[0113] In some embodiments, the RNA (e.g., mRNA) of the present invention is modified by replacing one or more uracils with a modified uracil. In one embodiment, the modified uracil comprises 1-methylpseudouracil, pseudouracil, 5-methyluracil, or a combination thereof. In one embodiment, the modified uracil comprises pseudouracil. In one embodiment, the modified uracil comprises 5-methyluracil. In one embodiment, the modified uracil comprises 1-methylpseudouracil.
[0114] In one embodiment, the RNA is modified by replacing at least one uracil with a modified uracil. In another embodiment, the RNA is modified by replacing all uracils with a modified uracil. In one embodiment, the proportion of modified uracil in the RNA is 10%-100%, for example, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%. In one embodiment, the proportion of modified uracil in the RNA is 20%-100%. In one embodiment, 20%-100% of the uracil in the RNA is replaced by 1-methylpseudouracil. In a preferred embodiment, 100% of the uracil in the RNA is replaced by 1-methylpseudouracil.
[0115] In one specific embodiment, the mRNA of the present invention comprises the nucleotide sequence of any one of SEQ ID NO:3-13, wherein 100% of uracil is replaced by 1-methylpseudouracil.
[0116] DNA
[0117] In some embodiments, the polynucleotide of the present invention is DNA. Such DNA can be, for example, a DNA template for transcribing the RNA of the present invention in vitro or a DNA vaccine for expressing polypeptide antigens in host cells. The DNA can be double-stranded, single-stranded, linear, or circular DNA.
[0118] The DNA template can be provided in a suitable transcription vector. Generally, the DNA template can be a double-stranded complex containing the same nucleotide sequence (coding strand) as the coding sequence described herein and a nucleotide sequence complementary to the coding sequence described herein (template strand). As known to those skilled in the art, the DNA template may contain a promoter, a 5'-UTR, a polypeptide coding sequence, a 3'-UTR, an optional poly(A) sequence, and a signal peptide coding sequence. The promoter can be a promoter available for a suitable RNA polymerase (particularly a DNA-dependent RNA polymerase) known to those skilled in the art, including but not limited to promoters of SP6, T3, and T7 RNA polymerases. In some embodiments, the 5'-UTR, coding sequence, 3'-UTR, and poly(A) sequence in the DNA template are the corresponding sequences contained in or complementary to the RNA described herein. The polynucleotides used as DNA vaccines can be provided in a plasmid vector (e.g., a circular plasmid vector).
[0119] In some embodiments, the DNA of the present invention comprises a coding sequence for a polypeptide antigen as described herein. In some embodiments, the DNA of the present invention comprises a coding sequence for a polypeptide as described herein. In some embodiments, the DNA of the present invention comprises, from the 5' end to the 3' end, (1) a T7 promoter, (2) a 5'-UTR, (3) a coding sequence, (4) a 3'-UTR, (5) an optionally present poly(A) sequence, and (6) a signal peptide coding sequence as described herein.
[0120] Composition
[0121] The present invention also provides a composition comprising the polynucleotide (particularly RNA) of the present invention. In one embodiment, the composition of the present invention is used to provide prophylactic and / or therapeutic immunity against rabies virus in a subject. In some embodiments, the composition of the present invention comprises the polynucleotide of the present invention. In some embodiments, the composition of the present invention comprises the DNA of the present invention. In some embodiments, the composition of the present invention comprises the RNA of the present invention. In one embodiment, the RNA is in vitro transcribed RNA. In one embodiment, the RNA is mRNA.
[0122] In some embodiments, the compositions of the present invention comprise polynucleotides (particularly RNA, such as mRNA) as described herein and lipids encapsulating said polynucleotides.
[0123] As used herein, the term "lipid" refers to an organic compound that contains a hydrophobic portion and optionally also a hydrophilic portion. Lipids are generally poorly soluble in water but soluble in many organic solvents. Typically, amphiphilic lipids containing both hydrophobic and hydrophilic portions can organize into a lipid bilayer structure in an aqueous environment, for example, existing in vesicle form. Lipids can include, but are not limited to, fatty acids, glycerides, phospholipids, sphingolipids, glycolipids, steroids, and cholesterol esters.
[0124] Particularly preferred nucleic acid compositions may be, for example, lipid nanoparticles (LNPs) as described herein. Methods for preparing such compositions can be found, for example, Kaczmarek, JC et al., 2017, Genome Medicine 9, 60, or as described herein. In some embodiments, the compositions of the present invention comprise lipid nanoparticles (LNPs). In some embodiments, the compositions of the present invention are lipid nanoparticles (LNPs) comprising the RNA of the present invention.
[0125] In some embodiments, the RNA (particularly mRNA) of the present invention is formulated as lipid nanoparticles (LNPs). As used herein, "lipid nanoparticles" or "LNPs" refers to particles formed of lipids in which nucleic acids (e.g., mRNA) are encapsulated.
[0126] In one embodiment, the LNP comprises the RNA of the present invention and lipids encapsulating the RNA, wherein the lipids encapsulating the RNA comprise cationic lipids, phospholipids, cholesterol, and polyethylene glycol-modified lipids.
[0127] cationic lipids
[0128] Cationic lipids are lipids that carry a net positive charge at a specified pH. Lipids with a net positive charge can associate with nucleic acids through electrostatic interactions.
[0129] Examples of cationic lipids include, but are not limited to, 1,2-di-O-octadecenyl-3-trimethylammonium-propane (DOTMA), 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), Diddecyldimethylammonium bromide (DDAB), 2,3-dioleoyloxy-N-[2(spermine carboxamide)ethyl]-N,N-dimethyl-l-propanamium trifluoroacetate (DOSPA), and dioctadecyldimethylammonium chloride. chloride, DODAC), 1,2-dioleoyl-3-dimethylammonium-propane, DODAP), 3-(N-(N′,N′-dimethylaminoethane)-carbamoyl)cholesterol, DC-Chol), 2,3-di(tetradecoxy)propyl-(2-hydroxyethyl)-dimethylazanium, D MRIE), N,N-dimethyl-3,4-dioleyloxybenzylamine (DMOBA), 1,2-dilinoleyloxy-N,N-dimethylaminopropane (DLinDMA), 1,2-dilinolenyloxy-N,N-dimethylaminopropane (DLenDMA), 3-dimethylamino-2-(cholest-5-ene-3-β-oxybutane-4-oxy)-1-(cis,cis-9,12-Octadecadienyloxy)propane (3-dimethylamino-2-(cholest-5-en-3-beta-oxybutan-4-oxy)-1-(cis,cis-9,12-oc-tadecadienoxy)propane, CLinDMA), N-(2-aminoethyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)propan-1-aminium bromide (N-(2-aminoethyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)propan-1-aminium) bromide (DMORIE), N,N-dimethyl-2,3-bis(dodecyloxy)propan-1-amine (DLDMA), N,N-dimethyl-2,3-bis(tetradecyloxy)propan-1-amine (DMDMA), dioctadecylamidoglycyl spermine (DOGS), N4-cholesteryl-spermine, 2,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (DLin-KC2-DMA), heptatriaconta-6,9,28,31-tetraen-19-yl-4-(dimethylamino)butyrate (heptatriaconta-6,9,28,31-tetraen-19-yl-4-(dimethylamino)butyrate) utanoate, DLin-MC3-DMA), heptadecan-9-yl-8-((2-hydroxyethyl)(6-oxo-6-((decyloxy)hexyl)amino)octanoate), ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate).
[0130] In some embodiments, the cationic lipid is preferably an ionizable cationic lipid. An ionizable cationic lipid carries a net positive charge at, for example, an acidic pH, and is neutral at a higher pH (e.g., physiological pH). Examples of ionizable cationic lipids include, but are not limited to: dioctadecylamidoglycylspermine (DOGS), N4-cholesteryl-spermine, DLin-KC2-DMA, and heptatriaconta-6,9,28,31-tetr. aen-19-yl-4-(dimethylamino)butanoate,DLin-MC3-DMA, heptadecan-9-yl-8-((2-hydroxyethyl)(6-oxo-6-((decyloxy)hexyl)amino)octanoate)(heptadecan-9-yl-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoate, ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate)((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate).
[0131] non-cationic lipids
[0132] In this document, "non-cationic lipids" refers to lipids that do not carry a net positive charge at a specified pH, such as anionic lipids and neutral lipids. The term "neutral lipids" refers to lipids that exist in an uncharged, neutral, or zwitterionic form at physiological pH. Neutral lipids may include, but are not limited to, phospholipids and steroids.
[0133] Examples of phospholipids include, but are not limited to: 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1-palmitoyl-2-oleoylphosphatidylethanolamine (POPE), distearoylphosphatidylcholine (DSPC), distearoyl-phosphatidylethanolamine (DSPE), dioleoylphosphatidylcholine (DOPC), dimyristoylphosphatidylcholine (DMPC), dipalmitoylphosphatidylcholine (DPPC), and arachidonicylphosphatidylcholine. Choline (diarachidoylphosphatidylcholine, DAPC), dibehenoylphosphatidylcholine (DBPC), ditricosanoylphosphatidylcholine (DTPC), diilignoceroylphosphatidylcholine (DLPC), palmitoyloleoyl-phosphatidylcholine (POPC), dipalmitoyl-phosphatidylethanolamine (DPPE), dimyristoyl-phosphatidylethanolamine (DMPE), and dilauroyl-phosphatidylethanolamine (DLPE).
[0134] Examples of steroids include, but are limited to, cholesterol, cholesterol alcohol, cholesterol ketone, cholesterolyl-2'-hydroxyethyl ether, cholesterolyl-4'-hydroxybutyl ether, tocopherol and its derivatives.
[0135] polyethylene glycol modified lipids
[0136] As used herein, the term "polyethylene glycol-modified lipid" refers to a molecule comprising both a polyethylene glycol moiety and a lipid moiety. Examples of polyethylene glycol-modified lipids include, but are not limited to, 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol (DMG-PEG), 1,2-dioleoyl-rac-glycero-methoxypolyethylene glycol (DOGPEG), and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-poly(ethylene glycol) (DSPE-PEG).
[0137] In one embodiment, the polyethylene glycol-modified lipid is DMG-PEG, such as DMG-PEG 2000.
[0138] Pharmaceutically acceptable excipients
[0139] Pharmaceutically acceptable excipients do not cause adverse physiological reactions. They are compatible with and stabilize the active ingredient to make the composition usable as a dosage form, and can be selected based on the intended route of administration and standard pharmaceutical practice. Examples include, but are not limited to, excipients, binders, diluents, lubricants, thickeners, surfactants, preservatives, stabilizers, emulsifiers, buffers, flavoring agents, coloring agents, pharmaceutically acceptable adjuvants, and pharmaceutically acceptable carriers. Examples of pharmaceutically acceptable adjuvants include, but are not limited to, aluminum salt adjuvants, metal adjuvants, oil-in-water emulsions, lipid adjuvants, protein adjuvants, nucleic acid adjuvants, plant-derived adjuvants, and gel adjuvants. Examples of pharmaceutically acceptable carriers include, but are not limited to, microcapsules / microspheres, liposomes, nanoparticles, polymeric micelles, emulsions (such as fat emulsions), protamine, viral vectors, bacterial vectors, fungal vectors, cell vesicles, conjugated couplers, and pharmaceutical polymers (such as PLGA, PEI, polycationic, and albumin). They are well-known in the pharmaceutical field; for example, other examples can be found in the Chinese Pharmacopoeia or Remington's Pharmaceutical Sciences.
[0140] Prevention and / or treatment of rabies virus infection
[0141] The present invention provides polynucleotides (especially RNA), compositions or vaccine formulations of the present invention for the prevention and / or treatment of rabies virus infection in subjects in need.
[0142] This invention provides the use of the polynucleotides (particularly RNA), compositions, or vaccine formulations of this invention in the preparation of medicaments for the prevention and / or treatment of rabies virus infection in subjects in need.
[0143] The present invention provides a method for preventing and / or preventing rabies virus infection in subjects in need, the method comprising administering to the subject a preventive or therapeutically effective amount of the polynucleotide (particularly RNA), composition, or vaccine formulation of the present invention.
[0144] In one embodiment, the method includes administering a composition containing mRNA of the present invention, particularly a composition containing LNP as described herein, for preventative or therapeutic purposes.
[0145] The term "preventive or therapeutic effective dose" refers to an amount sufficient to prevent or inhibit the occurrence of a disease or symptom and / or slow, alleviate, or delay its development or severity. Preventive or therapeutic effective doses are influenced by factors including, but not limited to, the rate and severity of disease or symptom development, the subject's age, sex, weight, and physiological condition, the duration of treatment, and the specific route of administration. Preventive or therapeutic effective doses may be administered in one or more doses. Preventive or therapeutic effective doses can be achieved through continuous or intermittent administration.
[0146] In some implementations, the effective dose for prevention or treatment is provided in one or more administrations.
[0147] In some implementations, the effective dose for prevention or treatment is provided in two applications.
[0148] In some implementations, the effective dose for prevention or treatment is provided in three applications.
[0149] In some implementations, the effective dose for prevention or treatment is provided over four administrations.
[0150] In some implementations, the effective dose for prevention or treatment is provided over five administrations.
[0151] In some preferred embodiments, the effective amount for prevention or treatment is provided in two applications.
[0152] In some preferred embodiments, the preventive or therapeutic effective amount is provided over four administrations.
[0153] Post-exposure prophylaxis (PEP) for rabies is a series of immunizations administered to subjects exposed to the rabies virus to prevent the onset of the disease. The WHO-recommended intramuscular PEP regimens include a 5-dose regimen (one dose each on days 0, 3, 7, 14, and 28, i.e., 1-1-1-1-1) and a 4-dose regimen (two doses on day 0, and one dose each on days 7 and 21, i.e., 2-1-1). The effective dose for prevention or treatment is provided in four or five administrations, respectively.
[0154] The present invention provides a method for post-exposure prophylaxis against rabies, the method comprising administering to a subject a prophylactic or therapeutically effective amount of the present invention’s polynucleotide (particularly RNA), composition, or vaccine formulation in accordance with an immunization schedule selected from the following: a 1-1-1 immunization schedule (one dose each on days 0, 7, and 28), a 2-1-1 immunization schedule (two doses on day 0, one dose each on days 7 and 21), a 2-2 immunization schedule (two doses on day 0, two doses on day 7), and a 2-1 immunization schedule (two doses on day 0, one dose on day 7).
[0155] In some embodiments, the polynucleotides, compositions, or vaccine formulations of the present invention are administered using a 1-1-1 immunization schedule.
[0156] In some embodiments, the polynucleotides, compositions, or vaccine formulations of the present invention are administered in a 2-2 immunization schedule.
[0157] In some embodiments, the polynucleotides, compositions, or vaccine formulations of the present invention are administered using a 2-1 immunization schedule.
[0158] In some embodiments, the polynucleotides, compositions, or vaccine formulations of the present invention are administered using a 2-1-1 immunization schedule.
[0159] The polynucleotide, composition, or vaccine formulation is administered via intramuscular injection.
[0160] In some embodiments, the polynucleotides, compositions, or vaccine formulations of the present invention may be administered to subjects by any method known to those skilled in the art, such as parenteral, oral, mucosal, percutaneous, intramuscular, intravenous, intradermal, subcutaneous, or intraperitoneal administration.
[0161] The compositions or vaccine formulations of the present invention are administered by intramuscular or intraperitoneal injection.
[0162] As used herein, the term "subject" describes an organism, such as a mammal, to which preventive or therapeutic immunity may be provided using the polynucleotides or compositions of the present invention. Preferably, the subject is a human.
[0163] The invention is further described with reference to the following embodiments. It should be understood that these embodiments are merely examples and do not constitute a limitation of the invention. All materials and instruments described below are commercially available or prepared according to methods known in the art. All experiments described below were performed according to the manufacturer's instructions or according to methods and procedures known in the art.
[0164] In the following examples, statistical analysis was performed using GraphPad Prism 8.0 software. Data are presented as the geometric mean with 95% confidence intervals or the arithmetic mean with standard errors. The dashed line on the y-axis indicates the limit of measurement. A two-tailed Mann-Whitney U test was used to compare two experimental groups, and a two-tailed Wilcoxon signed-rank test was used to compare the same animals at different time points. To compare more than two experimental groups, Kruskal-Wallis ANOVA and Dunn's multiple comparison test were applied. A p-value less than 0.05 was considered significant. *P<0.05, **P<0.01, ***P<0.001.
[0165] Example 1: Rabies virus glycoprotein G amino acid mutation design
[0166] This application uses rabies virus glycoprotein G as a vaccine immunogen, and the wild-type sequence of rabies virus glycoprotein G is SEQ ID NO:22:
[0167] Based on the wild-type, we designed two mutant rabies virus glycoproteins G, Mut#1 and Mut#2, using an internal algorithm. The computer simulation structures of wild-type rabies virus glycoprotein G and Mut#2 rabies virus glycoprotein G are compared in Figure 1A, where the wild-type on the left is in a monomeric form and the mutant on the right is in a dimer form.
[0168] The sequence of Mut#1 is SEQ ID NO:23:
[0169] The sequence of Mut#2 is SEQ ID NO:1:
[0170] Experimental animals: Female Balb / c mice, 6–7 weeks old, were used. The Balb / c mice (Zhuhai Baishitong Biotechnology Co., Ltd.) were bred and cared for at Guangzhou Yongnuo Biotechnology Co., Ltd. Animal studies were conducted strictly in accordance with the recommendations in the "Guidelines for the Breeding, Management and Use of Laboratory Animals".
[0171] Corresponding mRNAs were designed for wild-type protein G, Mut#1 protein G, and Mut#2 protein G, respectively. LNP-mRNA vaccine formulations were prepared according to the method in Example 3, and then mouse in vivo neutralizing antibody induction experiments were conducted according to the method in Example 5.
[0172] The full-length mRNA sequence expressing wild-type protein G is SEQ ID NO:24 (unoptimized codons):
[0173] The full-length mRNA sequence expressing Mut#1 protein G is SEQ ID NO:25 (unoptimized codons):
[0174] The full-length mRNA sequence expressing Mut#2 protein G is SEQ ID NO:26 (unoptimized codons):
[0175] The experimental results are shown in Figure 1B. Compared to the inactivated vaccine control, all LNP-mRNA vaccines exhibited significantly higher neutralizing antibody titers. Within the LNP-mRNA vaccine group, at day 7, the vaccine expressing Mut#2 protein G induced comparable neutralizing antibody titers to the vaccine expressing wild-type protein G. At day 14, the vaccine expressing Mut#2 protein G induced approximately 53% higher neutralizing antibody titers than the vaccine expressing wild-type protein G. This demonstrates the advantage of designing LNP-mRNA vaccines based on the amino acid sequence of Mut#2 protein G, and further optimization of LNP-mRNA vaccines based on Mut#2 protein G is recommended.
[0176] Example 2: Preparation of mRNA
[0177] 2.1 Design and synthesis of DNA templates
[0178] In short, to obtain mRNA sequences with optimal expression and structural stability in human cells, the inventors optimized human cell codons based on the aforementioned rabies virus glycoprotein G (amino acid sequence of SEQ ID NO:1) and designed DNA open reading frame (ORF) sequences encoding the amino acid sequence of SEQ ID NO:1. Ori is the original sequence of unoptimized codons, with the UTR and polyA tail removed compared to SEQ ID NO:26. Starting from Ori, Opti-11 was generated using the JCat sequence optimization method, and Opti-1, Opti-2, Opti-3, Opti-4, Opti-5, Opti-6, Opti-7, Opti-8, Opti-9, and Opti-10 were generated using an internally developed codon optimization method. Their sequences are shown in Table 1 below.
[0179] The T7 promoter sequence (TAATACGACTCACTATAAG, SEQ ID NO:14), 5'-UTR sequence (Control UTR, SEQ ID NO:18), 3'-UTR sequence (Control UTR, SEQ ID NO:19), and poly(A) sequence (100 adenosine nucleotides) were also designed. The 5'-UTR sequence contains the Kozak sequence “GCCACC”.
[0180] Then, the sequence of T7 promoter sequence, 5'-UTR sequence, signal peptide coding sequence (SEQ ID NO:17), DNA ORF, 3'-UTR sequence, and poly(A) sequence was followed and ligated into the vector pUC-Kan-TMA (Suzhou Genewiz Biotechnology Co., Ltd.). Primers were designed and based on high-fidelity DNA polymerase... PCR amplification was performed using a High-Fidelity DNA Polymerase kit (NEW ENGLAND BioLabs (NEB)). Finally, plasmid DNA templates were obtained through ligation, transformation, and bacterial sequencing.
[0181] Signal peptide coding sequence (SEQ ID NO:17):
[0182] 5'-UTR sequence (Control UTR, SEQ ID NO:18):
[0183] 3'-UTR sequence (Control UTR, SEQ ID NO:19):
[0184] 2.2 In vitro transcription of mRNA from DNA template
[0185] Using the purified linearized plasmid DNA prepared as in Example 2.1 as a template, in vitro transcription of RNA was performed via a co-transcriptional capping reaction using T7 RNA polymerase to generate Cap1 mRNA. In the in vitro transcription, 1-methyl-pseudouridine triphosphate was used instead of uridine triphosphate (UTP), therefore, the 1-methyl-pseudouridine modification ratio in the in vitro transcribed Cap1 mRNA was 100%. After transcription, the DNA template was digested using Dnase I (Thermo Fisher Scientific) to reduce the risk of residual DNA template.
[0186] The mRNA was purified using DynabeadsMyone (Thermo Fisher Scientific). The purified mRNA was dissolved in 1 mM sodium citrate buffer (pH 6.5+ / -0.1), aseptically filtered, and stored at -80°C until use. The obtained mRNA sequences are shown in Table 1.
[0187] Table 1. Sequences of nucleic acids Ori, Opti-1 to Opti-11
[0188] Example 3: Preparation of LNP-mRNA vaccine formulation
[0189] 3.1 Experimental Materials
[0190] The cationic lipid SM102 was synthesized according to the method described in WO2020219941A1. The cationic lipid HI, which the applicant previously developed, was synthesized according to the method described below. Cationic lipids ALC-0315 or Dlin-MC3 are readily available commercially. The core inventive point of this application is unrelated to cationic lipids or their formulation. Any cationic lipid used for the LNP formulation in the examples is acceptable, but it is necessary to ensure that the same LNP formulation is used in the same set of comparative verification experiments to allow direct comparison of the technical effects of different polynucleotide sequences in this application. The auxiliary phospholipid (DSPC) was purchased from Aivito (Shanghai) Pharmaceutical Technology Co., Ltd.; cholesterol, mPEG2000-DMG (i.e., DMG-PEG), was purchased from Xiamen Sinobond Biotechnology Co., Ltd.; and PBS was purchased from Invitrogen. The synthesis and preparation method of the HI cationic lipid compound is as follows:
[0191] Step 1:
[0192] Compound 1 (5 g, 65.79 mmol, 1.0 eq.) was dissolved in water (50 mL), and the solution was cooled to 0 °C before adding paraformaldehyde (11.39 g, 144.74 mmol, 2.2 eq.). The reaction mixture was then stirred at 50 °C for 4 hours. The reaction mixture was directly concentrated to dryness under reduced pressure, and the residue was purified by silica gel column chromatography (Changzhou Sante Technology) using 10% MeOH in DCM (Shanghai Anaiji Chemical) to obtain a milky white oily compound 2 (2.05 g, 22%).
[0193] LCMS: Rt: 0.558min; MS m / z (ELSD): 137.0[M+H]+.
[0194] Step 2:
[0195] Compound 2 (109 mg, 0.79 mmol, 1.0 eq.) and compound 3 were mixed together and added to ethanol (5 mL), then stirred overnight at 70 °C under nitrogen protection. The reaction was monitored by TLC (DCM:MeOH = 10 / 1), showing consumption of the starting material and the formation of a new principal spot. The reaction was quenched with water (50 mL) and extracted with ethyl acetate (50 mL × 3). The combined organic phases were washed with saturated brine (3 × 50 mL), dried over anhydrous sodium sulfate, filtered, and evaporated to dryness under reduced pressure. The residue was purified by silica gel column chromatography with 10% MeOH in DCM to give a colorless, transparent oily compound HI (217.57 mg, 32%).
[0196] LCMS: Rt: 1.538min; MS m / z (ELSD): 851.9[M+H]+.
[0197] 1H NMR (400MHz, CDCl3) δ6.40(s,2H),4.90–4.77(m,2H),4.23(s,4H),2.95–2.15(m,12H),1.76–1.18(m,72H),0.92–0.84(m,12H).
[0198] 3.2 Preparation of lipid nanoparticle formulations encapsulating mRNA (LNP-mRNA)
[0199] Preparation of mRNA aqueous solution: Dilute each mRNA prepared as in Example 2.2 to a 0.1 mg / mL mRNA solution with 50 mM citrate-sodium citrate buffer (pH 4.0).
[0200] Preparation of lipid solutions: Dissolve cationic lipid (SM102):DSPC:cholesterol:DMG-PEG 2000 in anhydrous ethanol at a molar ratio of 50:10:38.5:1.5 to prepare a 10 mg / mL lipid solution (unless otherwise specified, this formula is also used for other cationic lipids); Dissolve cationic lipid (HI):DSPC:cholesterol:DMG-PEG 2000 in anhydrous ethanol at a molar ratio of 42:8:48.5:1.5 to prepare a 10 mg / mL lipid solution.
[0201] Start waste = 0.5 mL, end waste = 0.1 mL, room temperature.
[0202] Preparation of LNP: The nucleic acid solution and lipid solution were mixed under the following conditions: Volume = 4.0 mL, Flow rate ratio = 1 (lipid solution): 3 (nucleic acid solution), Total flow rate = 12 mL / min, initial waste = 0.35 mL, final waste = 0.1 mL, room temperature, and diluted with ultrafiltrate to obtain the LNP solution.
[0203] Centrifugation and ultrafiltration: The LNP solution was subjected to ultrafiltration and centrifugation to remove ethanol (2000 rpm, 4℃) to obtain LNP-mRNAs of Ori, Opti-1, Opti-2, Opti-3, Opti-4, Opti-5, Opti-6, Opti-7, Opti-8, Opti-9, Opti-10, and Opti-11. A schematic diagram of LNP-mRNA vaccine preparation is shown in Figure 2A.
[0204] Example 4: Expression of candidate mRNA vaccine formulation in cells
[0205] A549 cells (non-small cell lung cancer cell line) were cultured in F-12K medium (Gibco) supplemented with 10% FBS and 1% penicillin-streptomycin at 37°C and 5% CO2.
[0206] The expression of 12 candidate LNP-mRNAs prepared as in Example 3.2 was verified in A549 cells. The specific method is as follows: A549 cells were seeded in 12-well plates (10... 5( / well), incubated overnight in a CO2 incubator. The Control UTR was ligated to Opti-1, Opti-2, Opti-3, Opti-4, Opti-5, Opti-6, Opti-7, Opti-8, Opti-9, Opti-10, Opti-11, and Ori mRNA, respectively, and then ligated into the vector pUC-Kan-TMA to obtain the recombinant vector pUC-Kan-TMA-UTR-mRNA. This was then processed using Lipofectamine. TM MessengerMAX TM Transfection reagent was used to transfect the ligated recombinant vector into each well (1 μg / well). Untransfected wells served as blank controls (NC). Cells in the wells were washed twice with pre-chilled PBS (1 mL / well) at 24 h, 48 h, and 72 h. The culture plates were then placed on ice and treated with Pierce PBS. TM Lyse the protease inhibitor with RIPA lysis buffer (Pulley) (100 μL / well), lyse thoroughly for 30 min, collect the cell lysate, centrifuge at 13000 rpm at 4℃ for 10 min, and collect the supernatant.
[0207] Cell lysis buffer (15 μL) from each sample was mixed with an equal volume of Novex. TMMix Tris-glycine SDS sample buffer (2×), add to the wells of an 8% PAGE-SDS electrophoresis gel, place in Tris-glycine-SDS electrophoresis buffer, run at 80V (30 min) followed by 120V (60 min), remove the electrophoresis gel, sandwich it with a PVDF membrane using the sandwich method, and transfer the membrane in an ice-water bath at a constant current of 300mA for 90 min. Remove the PVDF membrane, immerse it in 5% skim milk powder-TBST solution for 1 h, then immerse it in 1:1000 diluted anti-RABV-G antibody overnight at 4°C, wash the membrane three times with TBST, immerse it in 1:2000 diluted HRP-conjugated anti-mouse IgG antibody at room temperature for 1 h, wash the membrane three times with TBST, develop the color using SuperSignal West Atto ultrasensitive substrate, and photograph with a Tanon 5200 fluorescence microscope. Simultaneously, the expression of the internal control β-actin gene was detected using the same method. When comparing and analyzing the expression levels of the target gene, ImageJ was used to measure and statistically analyze the gray values of the target gene bands. Simultaneously, the total protein content of the samples was detected using the Beyotime BCA protein concentration assay kit. Finally, the expression level of the target gene in each transfected sample was calculated as: target gene band gray value / total sample protein content. This value was then input into Graphpad for plotting and analysis. The results are shown in Figure 2B: the LNP-mRNAs of Ori, Opti-1, Opti-2, Opti-3, Opti-4, Opti-5, Opti-6, Opti-7, Opti-8, Opti-9, Opti-10, and Opti-11 were all correctly translated into rabies virus G protein in cells, and their expression persisted for up to 72 hours. Furthermore, the relative protein expression values detected in A549 cell lysates transfected with mRNAs of Opti-1, Opti-2, Opti-3, Opti-4, Opti-5, Opti-6, Opti-7, Opti-8, Opti-9, Opti-10, and Opti-11 were still higher at 48h or 72h than the relative protein expression values detected on the surface of A549 cells transfected with mRNA Ori. This indicates that the optimized sequences (i.e., Opti-1, Opti-2, Opti-3, Opti-4, Opti-5, Opti-6, Opti-7, Opti-8, Opti-9, Opti-10, and Opti-11) have longer half-lives and more persistent expression than Ori, and the overall translation level throughout the expression process may be higher than that of Ori (unoptimized codons), thus achieving stronger immunogenicity.
[0208] Example 5: Induction of binding and neutralizing antibodies in mice by candidate mRNA vaccine formulations.
[0209] 5.1 Experimental Mice
[0210] This embodiment used female Balb / c mice, aged 6–7 weeks. The Balb / c mice (Zhuhai Baishitong Biotechnology Co., Ltd.) were bred and cared for at Guangzhou Yongnuo Biotechnology Co., Ltd. Animal research was conducted strictly in accordance with the recommendations in the "Guidelines for the Breeding, Management and Use of Laboratory Animals".
[0211] 5.2 Experimental Procedures and Results
[0212] In this embodiment, BALB / c mice were immunized with the LNP-mRNA formulation prepared as in Example 3.2 to evaluate the levels of binding antibodies and neutralizing antibodies (VNAs) induced in the mice.
[0213] Mice were randomly divided into 11 groups (n=4 or 5). Eight groups were immunized with the LNP-mRNA preparation as described in Example 3.2 (single dose of 5 μg (6 groups) and 10 μg (2 groups) / mice). Two groups were given a commercially available inactivated human rabies vaccine (antigen amino acid sequence UniProtKB:Q5JZZ2, hereinafter referred to as Control Vax, 0.1 dose) as a positive control. Some experiments used three doses of immunization (i.e., primary immunization on day 0, secondary immunization on day 7, and tertiary immunization on day 28), while some experiments used five doses of the inactivated vaccine (i.e., primary immunization on day 0, secondary immunization on day 3, tertiary immunization on day 7, quaternary immunization on day 14, and quintary immunization on day 28). The other group was given phosphate-buffered saline (PBS) as a negative control (PBS group). All groups were administered the vaccine via intramuscular injection on day 0 (primary immunization), day 7 (secondary immunization) (if applicable), and day 28 (tertiary immunization). Blood was collected from the orbital sinus of mice at 5, 7, 14, 28, 42, 56, 112 days and 6 months after the first immunization (see Figure 3A and E for the mouse immunization process). The rabies virus binding antibodies and neutralizing antibodies in the mouse serum were detected. The specific detection method is as follows:
[0214] ELISA (Enzyme-Linked Immunosorbent Assay) for detecting binding antibodies: G protein antigen (purchased from Atagenix) was diluted with ELISA coating buffer and coated with 25 ng / well of antigen onto a high-binding ELISA plate (Corning) overnight. The plate was washed in PBST (0.05% Tween-20) and blocked with 2.5% BSA (MACKLIN) in PBST. Serum samples were diluted with 2.5% BSA in PBST, with initial dilution titers ranging from 50 to 9000, followed by serial dilutions of 3-fold. A negative serum control was included in each plate. Add 100 μl of diluted serum sample to each well and incubate at 37°C (incubator) for 1 hour. Discard the serum sample and wash each well three times with 250 μl of PBST washing buffer. Add 100 μl of 2000-fold diluted secondary antibody (goat anti-mouse IgG HRP, Invitrogen) to each well and incubate at 37°C (incubator) for 1 hour. Discard the secondary antibody and wash each well three times with 250 μl of PBST washing buffer. After washing, add 100 μl of 3,3',5,5'-tetramethylbenzidine (TMB) (Solarbio) chromogenic solution to each well and develop in the dark for 15 minutes. Add 50 μl of stop solution (Solarbio) to each well to stop the reaction and detect the result. Read the OD value at 450 nm using a microplate reader (BioTek). The OD values of the serially diluted samples were plotted as curves. A nonlinear regression curve was fitted using Graphpad, and the dilution level at which the endpoint OD value was reached was calculated as the endpoint titer. (Sample OD) 450 nm is greater than the OD of the negative control group. 450 A value exceeding 3 times the standard deviation of nm is considered positive.
[0215] Neutralizing antibodies were detected using the PBNA (pseudovirus-based neutralization assay), a method described in the literature (Nie J, Wu X, Ma J, Cao S, Huang W, Liu Q, Li X, Li Y, Wang Y. Development of in vitro and in vivo rabies virus neutralization assays based on a high-titer pseudovirus system. Sci Rep. 2017 Feb 20; 7:42769. doi:10.1038 / srep42769.PMID:28218278; PMCID:PMC5316940.): 50 μL of serially tripled test serum was prepared in 100 μL volumes on a 96-well plate. Each sample was added to four adjacent wells. 50 μL of 1600 TCID32 was added to each well. 50 The CVS-11 pseudovirus was prepared internally and its viral titer was confirmed. Then, the 96-well plate was incubated in a 37°C, 5% CO2 incubator for 1 hour. After 1 hour, the plate contained 4 × 10⁻⁶ CVS-11 pseudoviruses. 4 50 μL of 293T cell (ATCC, CRL3216) suspension was added to each well and incubated at 37°C in a 5% CO2 incubator for 48 hours. After incubation, a portion of the culture medium was aspirated, leaving 100 μL / well. 100 μL of Bright-Glo luciferase substrate (Promega, Madison, WI) was added to each well, and the mixture was incubated at room temperature for 2 min. 150 μL from each well was then transferred to a black 96-well plate. The fluorescence value of each well was detected using a Glomax 96 microplate luminometer (Promega, Madison, WI). The fluorescence values of the serially diluted samples were fitted using nonlinear regression analysis with GraphPad Prism 6 (GraphPad Software, Inc., San Diego, CA) to calculate the half-maximal inhibitory titer (EC50) of the serum sample. 50 value).
[0216] Cellular immune response levels were detected using the ELISPOT method, as shown in Figure 3C-3. Mice received the vaccine on days 0, 7 (optional), and 8 (optional). Four months later, the spleens of the mice were harvested for cellular immune response testing. The spleens were harvested as follows: immunized mice were euthanized, and the spleens were aseptically removed. The spleens were placed on a 70 μm cell filter and gently ground using a 2 mL syringe plunger. The cells were then washed and filtered with FACS buffer (sterile PBS, pH 7.2, containing 2% fetal bovine serum). The cell suspension was collected and centrifuged at 1500 rpm for 5 min at 4°C. The supernatant was discarded, and the bottom of the tube was gently tapped to loosen the precipitate. 4 mL of erythrocyte lysis buffer (1X, Biolegend, catalog number 420301) was added, and lysis was performed at room temperature for 5 min with intermittent shaking. 4 mL of FACS buffer was added to terminate lysis, and the cells were centrifuged again (4°C, 1500 rpm, 5 min), discarding the supernatant. Resuspend the cells in 10 mL of FACS buffer, filter through a 70 μm filter, and take 50 μL of the cell suspension to dilute 10-fold in 450 μL of FACS buffer. Take 10 μL of the diluted cell suspension and add it to 40 μL of 0.4% trypan blue staining solution to count viable cells. Adjust the cell density to 2 × 10⁻⁶ cells / mL. 7 Cells / mL were placed in complete culture medium (RPMI 1640 medium containing 10% fetal bovine serum, 100 U / mL penicillin, and 100 μg / mL streptomycin). 200 μL of this cell suspension (2 × 10⁻⁶ cells / mL) was then added. 7 Add (cells / mL) to 600 μL of complete culture medium, mix well, and obtain 5 × 10⁻⁶ cells / mL. 6 Cell suspensions of cells / mL were used for subsequent cell seeding, culture, and assays. Subsequent cell seeding, culture, and assays followed the standard workflow outlined in the manuals of Dakota Biotechnology's ELISPOT series kits (Cat#: 2210003 and 2210403).
[0217] As shown in Figure 3A, mice were immunized three times (D0 / D7 / D28) with 10 μg mRNA-LNP vaccine and control inactivated vaccine. Serum was collected on D7, D14 and 6 months after the first immunization to detect the levels of neutralizing antibody and binding antibody. The results are shown in Figure 3B. After immunization with LNP-mRNA Ori, LNP-mRNA Opti-11, Control Vax, and PBS, compared to the PBS group, 10 μg LNP-mRNA Ori, LNP-mRNA Opti-11, and 0.1 dose Control Vax induced neutralizing antibodies as early as day 7 post-immunization. Furthermore, the EC50 levels of neutralizing antibodies induced by 10 μg LNP-mRNA Ori and LNP-mRNA Opti-11 were 4-5 times (8754.4, 7120.8, 1754.3) and 7-9 times (24270.4, 29966.4, 3272) higher than those induced by inactivated vaccines on days 7 and 14, respectively (Figure 3B). The EC50 level of neutralizing antibodies with LNP-mRNA Opti-11 on day 7 was slightly lower than that with LNP-mRNA Ori, but surpassed that of LNP-mRNA on day 14. Ori, consistent with the results of cell expression antigen protein levels in Example 4, demonstrates that sustained antigen protein expression does indeed induce more durable neutralizing antibody levels. Furthermore, the EC50 level of neutralizing antibodies produced by Opti-11 6 months after three immunizations (21752.2) remained 7 times higher than the EC50 level induced by the inactivated vaccine (2983.8) (Figure 3, C-1); the neutralizing antibody titers produced by Opti-11 4 and 6 months after three immunizations remained 22.3 times and 11.4 times higher than those induced by the inactivated vaccine, respectively (Figure 3, C-2). These results demonstrate that the LNP-mRNA technology platform exhibits advantages in immunogenicity and immune memory compared to inactivated vaccines under the same immunization schedule. Within the scope of the LNP-mRNA technology platform, Opti-11, obtained through sequence optimization, is superior to Ori without sequence optimization. Furthermore, referring to the ELISPOT assay results for cellular immune responses in Figure 3 (C-3), no signs of IFN-γ secretion were observed macroscopically in either the inactivated vaccine immunized group or the non-immunized group (PBS), while IFN-γ secretion was visible macroscopically in the LNP-mRNA Opti-11 group. This indicates that compared to traditional inactivated vaccines, LNP-mRNA vaccines can induce both humoral immunity (producing neutralizing antibodies) and cellular immunity, theoretically possessing a differentiated protective mechanism not found in traditional inactivated vaccines. Figure 3 (C-3) shows that at least a 5ug dose of LNP-mRNA Opti-11 is required for a good cellular immune response, and the cellular immune response induced by three injections is significantly stronger than that induced by only one or two injections.
[0218] Furthermore, the candidate sequences among the mRNA sequences Opti-1, Opti-2, Opti-3, Opti-4, Opti-5, Opti-6, Opti-7, Opti-8, Opti-9, and Opti-10 obtained using the internal mRNA sequence optimization method based on Opti-11 were verified to be superior to Opti-11, as shown in Figure 2B. The expression of mRNA Opti-1 and Opti-8 was significantly better than Opti-11 at 48h or 72h, and the expression of Opti-9 was also better than Opti-11 at 48h or 72h. The expression persistence trend of mRNA Opti-2 was also significantly better than that of Opti-11. They can be used as candidates for in vivo immunogenicity studies. Therefore, the levels of binding antibody titers in the serum of mice immunized with 5 μg LNP-mRNA Opti-1, Opti-2, Opti-9, and Opti-11 on day 7 were detected using ELISA. The results showed (as shown in Figure 3, D) that mRNA Opti-1 (93996.3) induced a higher level of binding antibody on day 7 compared to Opti-2 (47946.5), Opti-9 (55945.6), and Opti-11 (51102.6), approximately 1.8 times higher than Opti-11. Therefore, Opti-1 was selected as a candidate sequence, and Opti-8, the mRNA with the highest expression level at 48 h, was also selected for immunogenicity comparison with the inactivated vaccine to simulate a post-exposure immunoprophylaxis scenario. The experimental protocol is shown in Figure 3E. BALB / c mice were immunized with the WHO-recommended five-dose post-exposure prophylaxis regimen (D0 / D3 / D7 / D14 / D28) using a control inactivated vaccine (Control Vax) (0.1 human dose / mouse), and BALB / c mice were immunized with three doses (D0 / D7 / D28) of mRNA vaccine (LNP-mRNA Opti-1 and LNP-mRNA Opti-8) (5 μg / mouse).Following the initial immunization, the binding antibody titers produced by the two LNP-mRNA vaccines on days 5 and 7 were higher than those of the control inactivated vaccine (2897.6, 2685.7, and 1025.6 on day 5, and 17361.3, 36996.4, and 4239.8 on day 7, respectively). Specifically, the binding antibody titer induced by the LNP-mRNA Opti-8 vaccine on day 7 was significantly higher than that induced by the control inactivated vaccine. From day 14 to day 112 (4 months after the initial immunization) following the second immunization (day 7), the binding antibody titers produced by both LNP-mRNA vaccines were significantly higher than those of the control inactivated vaccine (as shown in Figure 3, F-1). These results indicate that the mRNA vaccines prepared from the two selected mRNA ORF sequences, Opti-1 and Opti-8, can produce binding antibody titers superior to the control inactivated vaccine with only 3 immunizations, and a single immunization can produce higher early binding antibody levels than the control inactivated vaccine after two immunizations. Referring to F-2 in Figure 3, on day 14 after the second immunization, the EC50 levels of binding antibodies against LNP-mRNA Opti-1 and LNP-mRNA Opti-8 were 9.7 times and 7.2 times higher than those of the control inactivated vaccine, respectively. On day 56, the EC50 levels of binding antibodies against LNP-mRNA Opti-1 and LNP-mRNA Opti-8 reached their peak, being 16.2+ times and 14.5 times higher than those of the control inactivated vaccine, respectively. Even at day 112, the EC50 levels of binding antibodies against LNP-mRNA Opti-1 and LNP-mRNA Opti-8 were still 8.8 times and 9.9 times higher than those of the control inactivated vaccine, respectively.
[0219] Example 6: Immunogenicity of Opti-11 LNP-mRNA formulation under different immunization schedules
[0220] 6.1 Experimental Mice
[0221] This embodiment used female Balb / c mice, aged 6–7 weeks. The Balb / c mice (Zhuhai Baishitong Biotechnology Co., Ltd.) were bred and cared for at Guangzhou Yongnuo Biotechnology Co., Ltd. Animal research was conducted strictly in accordance with the recommendations in the "Guidelines for the Breeding, Management and Use of Laboratory Animals".
[0222] 6.2 Experimental Procedures and Results
[0223] To confirm the immunogenicity advantage of the mRNA vaccine, the early preliminary optimized sequence was used to test the LNP-mRNA vaccine in mice with low, medium, and high doses of single and double-dose immunization. Serum was collected on days 7 and 14 after the first immunization to detect the level of neutralizing antibodies in the serum, thereby verifying the immunogenicity (vaccine efficacy) of the mRNA vaccine. The results are shown in Figure 4. When mice were immunized with LNP-mRNA Opti-11 (2.5 μg, 5 μg, 10 μg / mouse) using a single-dose (D0) and two-dose (D0 / D7) immunization program, the neutralizing antibody levels produced by the 2.5 μg and 5 μg doses were comparable on day 7 after the first immunization, at 9137.2 and 7897.2, respectively; the neutralizing antibody level produced by the 10 μg dose was 10012, slightly higher than that of the 2.5 μg and 5 μg doses. These results indicate that 2.5 μg of LNP-mRNA Opti-11 can achieve good immunogenicity. Comparing the serum levels of neutralizing antibodies on day 14 after immunization with 5 μg of one dose (D0) and two doses (D0 / D7), the level of neutralizing antibodies produced by two doses was 45485, while the level of neutralizing antibodies produced by one dose was 27262.7. The immunogenicity of two doses was higher than that of one dose, indicating that the second immunization on day 7 has a enhancing effect on immunogenicity.
[0224] Example 7: Immunogenicity of LNP-mRNA formulations of Opti-1 and Opti-8 compared with the immunogenicity of benchmarks on the same technology platform.
[0225] 7.1 Experimental Mice
[0226] This embodiment used female Balb / c mice, aged 6–7 weeks. The Balb / c mice (Zhuhai Baishitong Biotechnology Co., Ltd.) were bred and cared for at Guangzhou Yongnuo Biotechnology Co., Ltd. Animal research was conducted strictly in accordance with the recommendations in the "Guidelines for the Breeding, Management and Use of Laboratory Animals".
[0227] 7.2 Experimental Procedures and Results
[0228] To demonstrate the advantages of the optimized Opti mRNA sequence, a vaccine sequence from the same mRNA technology platform (SEQ ID NO.2 in Zhuhai Lifanda-CN110714015B) was used as a benchmark. The Control UTR (5'-UTR, SEQ ID NO:18; 3'-UTR, SEQ ID NO:19) mentioned above was used to link mRNA Opti-8, i.e., Opti-8 Control UTR; and the self-developed UTR (5'-UTR, SEQ ID NO:15; 3'-UTR, SEQ ID NO:16, i.e., UTR) was used to link mRNA Opti-8, i.e., Opti-8 UTR. The experimental protocol is shown in Figure 5A. After mice were immunized twice with LNP-mRNA vaccine (5μg / mouse) (D0 / D7), serum was collected on D28 to detect neutralizing antibodies. The results are shown in Figure 5B. On day 28 after the first immunization, the neutralizing antibody titer induced by LNP-mRNA Opti-8 Control UTR was 9633.8, which was slightly higher than the neutralizing antibody titer induced by Benchmark (8916.8), proving that the Opti-8 sequence has stronger immunogenicity than Benchmark. Replacing the Control UTR with the self-developed UTR LNP-mRNA Opti-8 UTR further improved the neutralizing antibody titer to 13426.5. For Opti-1, another candidate sequence whose immunogenicity has been verified, in another experiment using the same protocol, a control UTR was used to link Opti-1 and Opti-8 respectively. Mice were immunized twice with 5 μg of LNP-mRNA on D0 / D7. On D28, mouse serum was collected to detect neutralizing antibodies. The results are shown in Figure 5C. The level of neutralizing antibodies induced by LNP-mRNA Opti-1 Control UTR was 12762.2, which was slightly higher than the level of neutralizing antibodies induced by LNP-mRNA Opti-8 Control UTR (11135.8). The results in Figure 5 show that the mRNA vaccines expressing ORF sequences with Opti-1 and Opti-8 as antigens have stronger immunogenicity than the benchmark sequences on the same technology platform.
[0229] Self-developed 5'-UTR (SEQ ID NO:15):
[0230] Self-developed 3'-UTR (SEQ ID NO:16):
[0231] Example 8: The LNP-mRNA combined with the mouse BAFF gene of the present invention enhances immunogenicity.
[0232] 8.1 Experimental Mice
[0233] This embodiment used female Balb / c mice, aged 6–7 weeks. The Balb / c mice (Zhuhai Baishitong Biotechnology Co., Ltd.) were bred and cared for at Guangzhou Yongnuo Biotechnology Co., Ltd. Animal research was conducted strictly in accordance with the recommendations in the "Guidelines for the Breeding, Management and Use of Laboratory Animals".
[0234] 8.2 Experimental Procedures and Results
[0235] To explore ways to enhance vaccine immunogenicity based on Opti mRNA, murine BAFF mRNA and Opti-1 mRNA were used together. The murine BAFF mRNA and Opti-1 mRNA were separately formulated and then mixed 1:1 (the formulation method of BAFF mRNA is the same as in Examples 2 and 3). Mice were immunized (5 μg of each mRNA, i.e., 10 μg of LNP-mRNA / mouse) (4 mice / group), and mice immunized with only LNP-Opti-1 mRNA (5 μg / mouse) (3 mice / group) served as a control. Serum was collected on day 7 after the first immunization, and specific binding antibodies were detected using ELISA. The results are shown in Figure 6. The binding antibody level induced by BAFF Opti-1 mRNA was 1844.3, which was higher than the binding antibody level induced by the control group (Opti-1 only) (1058.9), demonstrating that the introduction of BAFF mRNA into the formulation can enhance immunogenicity.
[0236] BAFF ORF mRNA (SEQ ID NO:20):
[0237] BAFF gene amino acid sequence (SEQ ID NO:21):
[0238] Example 9: The LNP-mRNA combined with adjuvant of the present invention enhances immunogenicity.
[0239] laboratory mice
[0240] This embodiment used female Balb / c mice, aged 6–7 weeks. The Balb / c mice (Zhuhai Baishitong Biotechnology Co., Ltd.) were bred and cared for at Guangzhou Yongnuo Biotechnology Co., Ltd. Animal research was conducted strictly in accordance with the recommendations in the "Guidelines for the Breeding, Management and Use of Laboratory Animals".
[0241] Following the method of Example 3, LNP-mRNA containing the adjuvant compound was prepared by additionally incorporating 10% molar amount of the heterocyclic adjuvant compound HA-1A (the structural formula is shown below, and compound HA-1A can be prepared according to the method described in WO2026046400A1) into the LNP formulation.
[0242] Serum was collected on days 5 and 7 after a single immunization, and the specific binding antibody was detected by ELISA. The results are shown in Figure 7. The EC50 level induced by LNP-Opti-1 mRNA with adjuvant compound was significantly increased compared with that of the control group (LNP-Opti-1 mRNA without adjuvant compound) (EC50 was tested according to the PBNA method in Example 5), demonstrating that the introduction of adjuvant compound into the formulation can enhance immunogenicity.
[0243] While specific embodiments of the present invention have been described above, those skilled in the art should understand that these are merely illustrative examples, and various changes or modifications can be made to these embodiments without departing from the principles and essence of the present invention. Therefore, the scope of protection of the present invention is defined by the appended claims.
Claims
1. A rabies virus glycoprotein G, characterized in that, It contains the amino acid sequence shown in SEQ ID NO:
1.
2. A polynucleotide, characterized in that, The polynucleotide encodes the rabies virus glycoprotein G as described in claim 1.
3. The polynucleotide as described in claim 2, characterized in that, The ORF sequence of the polynucleotide is shown in SEQ ID NO:3-13.
4. The polynucleotide as described in claim 2, characterized in that, The polynucleotide is RNA, for example, mRNA; Preferably, the polynucleotide further comprises one or more of 5'-UTR, 3'-UTR, and 3'poly(A); More preferably, the nucleotide sequence of the 5'-UTR is as shown in SEQ ID NO:15 or SEQ ID NO:18; the nucleotide sequence of the 3'-UTR is as shown in SEQ ID NO:16 or SEQ ID NO:19; the 3'poly(A) contains 50-120 adenosine nucleotides; the 3'poly(A) preferably contains 100 adenosine nucleotides.
5. A polynucleotide composition, characterized in that, The polynucleotide composition comprises the polynucleotide as described in claim 2, 3 or 4 and the murine BAFF gene; Preferably, the nucleic acid sequence of the mouse-derived BAFF gene is shown in SEQ ID NO:
20.
6. A recombinant expression vector, characterized in that, The recombinant expression vector comprises the polynucleotide as described in claim 2, 3, or 4, or the polynucleotide composition as described in claim 5; Preferably, the backbone of the recombinant expression vector is a plasmid or a virus, such as pUC-Kan-TMA.
7. A transformant, characterized in that, The transformant comprises the polynucleotide as described in claim 2, 3 or 4, the polynucleotide composition as described in claim 5, or the recombinant expression vector as described in claim 6; Preferably, the starting cell of the transformant is a eukaryotic cell; More preferably, the eukaryotic cell is a mammalian cell; More preferably, the mammalian cell is a human somatic cell.
8. A method for preparing recombinant rabies virus glycoprotein, characterized in that, The method includes culturing the transformant as described in claim 7 under conditions suitable for the expression of the recombinant rabies virus glycoprotein.
9. A polynucleotide delivery system, characterized in that, The polynucleotide delivery system comprises (1) a polynucleotide as described in claim 2, 3 or 4, a polynucleotide composition as described in claim 5, a recombinant expression vector as described in claim 6 or a transformant as described in claim 7; and (2) a delivery vector; Preferably, the delivery carrier is a lipid nanoparticle; More preferably, the lipid nanoparticles include cationic lipids, non-cationic lipids, sterols, and polyethylene glycol-modified lipids; More preferably, the lipid nanoparticles include the adjuvant compound HA-1A.
10. A pharmaceutical composition, characterized in that, The pharmaceutical composition comprises rabies virus glycoprotein G as described in claim 1 or a polynucleotide delivery system as described in claim 9; optionally, it further comprises pharmaceutically acceptable excipients.
11. An mRNA rabies vaccine, characterized in that, The mRNA rabies vaccine comprises the rabies virus glycoprotein G as described in claim 1, the polynucleotide as described in claim 2, 3 or 4, the polynucleotide composition as described in claim 5, the polynucleotide delivery system as described in claim 9, and / or the pharmaceutical composition as described in claim 10. Preferably, the mRNA rabies vaccine further comprises a pharmaceutically acceptable adjuvant; the mRNA rabies vaccine is administered via subcutaneous injection, intramuscular injection, or intraperitoneal injection; More preferably, the administration is performed according to a 1-1-1-1 immunization schedule, a 2-1-1-1 immunization schedule, a 2-2 immunization schedule, a 2-1 immunization schedule, or a 2-1-1 immunization schedule; the dosage of the administration is 0.08–10 μg. More preferably, the dosage is 0.08–2.5 μg; More preferably, the dosage is 0.08–2 μg.
12. A reagent kit or medicine box, characterized in that, The kit or cassette comprises the rabies virus glycoprotein G as described in claim 1, the polynucleotide as described in claim 2, 3 or 4, the polynucleotide composition as described in claim 5, the recombinant expression vector as described in claim 6, the transformant as described in claim 7, the polynucleotide delivery system as described in claim 9, the pharmaceutical composition as described in claim 10, and / or the mRNA rabies vaccine as described in claim 11.
13. Use of the rabies virus glycoprotein G of claim 1, the polynucleotide of claim 2, 3 or 4, the polynucleotide composition of claim 5, the recombinant expression vector of claim 6, the transformant of claim 7, the polynucleotide delivery system of claim 9, the pharmaceutical composition of claim 10, the mRNA rabies vaccine of claim 11, and / or the kit or cassette of claim 12 in the preparation of medicaments and / or diagnostic reagents for the prevention and treatment of rabies virus infection.
